Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastroesophageal Reflux 2Barrett Esophagus 2Zollinger-Ellison Syndrome 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × YF 476 × Clear all
NCT01298999 2021-11-23

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Columbia University

Phase 2 Completed
27 enrolled 16 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT02597712 2021-04-12

YF476 in Barrett's Esophagus

Trio Medicines Ltd.

Phase 2 Completed
27 enrolled 15 charts
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux

NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated
3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡